Univariate analysis of the prognostic factors in children and adolescents with extranodal nasal-type NK/T-cell lymphoma
| . | 5-year OS . | 5-year PFS . | ||
|---|---|---|---|---|
| % . | P . | % . | P . | |
| Age, y | ||||
| 16 or younger | 72.7 | .463 | 65.7 | .955 |
| Older than 16 | 79.2 | 73.2 | ||
| Sex | ||||
| Male | 80.6 | .58 | 64.9 | .877 |
| Female | 71.4 | 75.2 | ||
| ECOG score | ||||
| 0 or 1 | 72.6 | .146 | 66.5 | .495 |
| 2 or 3 | 100 | 80.0 | ||
| Primary site | ||||
| Nasal cavity | 66.1 | .083 | 62.2 | .160 |
| Waldeyer ring | 90.9 | 84.0 | ||
| Stage | ||||
| IE | 77.9 | .514 | 67.7 | .469 |
| IIE | 78.6 | 71.4 | ||
| B symptoms | ||||
| Yes | 80.2 | .758 | 66.1 | .877 |
| No | 75.3 | 70.3 | ||
| LDH | ||||
| Normal | 80.0 | .301 | 68.9 | .834 |
| High | 72.2 | 62.3 | ||
| Cervical lymph node involved | ||||
| Yes | 73.8 | .960 | 67.2 | .541 |
| No | 81.9 | 68.6 | ||
| Age-adjusted IPI | ||||
| 0 | 80.0 | .343 | 79.6 | .514 |
| 1 | 68.9 | 64.2 | ||
| CR after therapy | ||||
| CR | 84.8 | .006 | 77.3 | .000 |
| Not CR | 30.0 | 0 | ||
| . | 5-year OS . | 5-year PFS . | ||
|---|---|---|---|---|
| % . | P . | % . | P . | |
| Age, y | ||||
| 16 or younger | 72.7 | .463 | 65.7 | .955 |
| Older than 16 | 79.2 | 73.2 | ||
| Sex | ||||
| Male | 80.6 | .58 | 64.9 | .877 |
| Female | 71.4 | 75.2 | ||
| ECOG score | ||||
| 0 or 1 | 72.6 | .146 | 66.5 | .495 |
| 2 or 3 | 100 | 80.0 | ||
| Primary site | ||||
| Nasal cavity | 66.1 | .083 | 62.2 | .160 |
| Waldeyer ring | 90.9 | 84.0 | ||
| Stage | ||||
| IE | 77.9 | .514 | 67.7 | .469 |
| IIE | 78.6 | 71.4 | ||
| B symptoms | ||||
| Yes | 80.2 | .758 | 66.1 | .877 |
| No | 75.3 | 70.3 | ||
| LDH | ||||
| Normal | 80.0 | .301 | 68.9 | .834 |
| High | 72.2 | 62.3 | ||
| Cervical lymph node involved | ||||
| Yes | 73.8 | .960 | 67.2 | .541 |
| No | 81.9 | 68.6 | ||
| Age-adjusted IPI | ||||
| 0 | 80.0 | .343 | 79.6 | .514 |
| 1 | 68.9 | 64.2 | ||
| CR after therapy | ||||
| CR | 84.8 | .006 | 77.3 | .000 |
| Not CR | 30.0 | 0 | ||
OS indicates overall survival; PFS, progression-free survival; RT, radiotherapy; CT, chemotherapy; CR, complete remission; PR, partial remission; SD, stable disease; and PD, progression disease.